Table of Contents
Frontotemporal dementia is the most common form of dementia in people under 65, and there is no approved disease-modifying treatment. AviadoBio is one of the few clinical-stage companies trying to fix that, by putting a missing protein back into the part of the brain where it is needed.
AviadoBio is running three CNS gene therapy programs and recently announced a capsid partnership with Apertura to take its silencing platform from rare disease into Alzheimer's.
The London-based clinical-stage company has three active programs across the central nervous system. Its lead, in frontotemporal dementia caused by GRN mutations, just completed its fourth dosing cohort and is on track to finish dosing in early H2 2026, with the therapy delivered intraparenchymally to the thalamus to bypass the blood-brain barrier. A Eugenics-partnered optogenetics program for inherited retinal disorders is also in the clinic, and a third program, AVB-406, is heading into toxicology, pairing AviadoBio's in-house micro-RNA gene silencing platform with the newly partnered Apertura capsid that targets the human transferrin receptor. AviadoBio also kicked off a new financing round a few weeks ahead of the interview and is actively in market with investors.
At Meeting on the Med 2026, reporting for Onyx, Federico Citterich sat down with Lisa Deschamps to find out more.
A special thanks to our Onyx Live sponsors:
Cellares - delivering cell therapy manufacturing excellence at scale across a global network of IDMO smart factories https://www.cellares.com/
Comments